Bioxcel therapeutics announces promising topline results from part 1 of pivotal serenity iii trial of bxcl501 for at-home use in acute treatment of agitation in bipolar disorders or schizophrenia

Clinically meaningful efficacy results observed with half (60mcg) of the approved dose of igalmi™ greater than 50% pec response rate attained; proportionally consistent with dose response when compared to rates seen in serenity i and ii bxcl501 was well tolerated and demonstrated favorable safety results supporting potential for at-home use serenity iii part 2 planned as an adaptive trial design with 60mcg and 80mcg to potentially address agitation spectrum for patients at home company to hold conference today at 8 a.m. et  new haven, conn.
BTAI Ratings Summary
BTAI Quant Ranking